# Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19

> **NCT04348474** · EARLY_PHASE1 · SUSPENDED · sponsor: **Azidus Brasil** · enrollment: 200 (estimated)

## Conditions studied

- Covid-19

## Interventions

- **DRUG:** Hydroxychloroquine Sulfate
- **DRUG:** Azithromycin Tablets

## Key facts

- **NCT ID:** NCT04348474
- **Lead sponsor:** Azidus Brasil
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-04-20
- **Primary completion:** 2020-06-30
- **Final completion:** 2023-07
- **Target enrollment:** 200 (ESTIMATED)
- **Why stopped:** Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.
- **Last updated:** 2022-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04348474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04348474, "Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04348474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*